{"title":"阿尔维莫泮治疗术后肠梗阻:我们应该知道些什么?","authors":"Abhijit Nair","doi":"10.1016/j.aat.2016.10.001","DOIUrl":null,"url":null,"abstract":"<div><p>Alvimopan is an US-FDA approved, peripherally acting mu opioid receptor antagonist which when started pre-operatively has been shown to hasten intestinal motility and reduce the duration of post-operative ileus. However the logistics involved in procuring, storing and dispensing the drug and the cost of the drug for fifteen doses as approved by FDA prohibits the use of it on a regular basis.</p></div>","PeriodicalId":87042,"journal":{"name":"Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists","volume":"54 3","pages":"Pages 97-98"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.aat.2016.10.001","citationCount":"11","resultStr":"{\"title\":\"Alvimopan for post-operative ileus: What we should know?\",\"authors\":\"Abhijit Nair\",\"doi\":\"10.1016/j.aat.2016.10.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Alvimopan is an US-FDA approved, peripherally acting mu opioid receptor antagonist which when started pre-operatively has been shown to hasten intestinal motility and reduce the duration of post-operative ileus. However the logistics involved in procuring, storing and dispensing the drug and the cost of the drug for fifteen doses as approved by FDA prohibits the use of it on a regular basis.</p></div>\",\"PeriodicalId\":87042,\"journal\":{\"name\":\"Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists\",\"volume\":\"54 3\",\"pages\":\"Pages 97-98\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.aat.2016.10.001\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1875459716300947\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875459716300947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Alvimopan for post-operative ileus: What we should know?
Alvimopan is an US-FDA approved, peripherally acting mu opioid receptor antagonist which when started pre-operatively has been shown to hasten intestinal motility and reduce the duration of post-operative ileus. However the logistics involved in procuring, storing and dispensing the drug and the cost of the drug for fifteen doses as approved by FDA prohibits the use of it on a regular basis.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
